Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
Authors:
- Mohammad M. GhahremanpourMGMohammad M. Ghahremanpour
- Julian Tirado-RivesJTJulian Tirado-Rives
- Maya DeshmukhMDMaya Deshmukh
- Joseph A. IppolitoJIJoseph A. Ippolito
- Chun-Hui ZhangCZChun-Hui Zhang
- Israel Cabeza de VacaIVIsrael Cabeza de Vaca
- Maria-Elena LiosiMLMaria-Elena Liosi
- Karen S. AndersonKAKaren S. Anderson
- William L. JorgensenWJWilliam L. Jorgensen
Preprint
Abstract
A consensus virtual screening protocol has been applied to ca. 2000 approved drugs to seek inhibitors of the main protease (M pro ) of SARS-CoV-2, the virus responsible for COVID-19. 42 drugs emerged as top candidates, and after visual analyses of the predicted structures of their complexes with M pro , 17 were chosen for evaluation in a kinetic assay for M pro inhibition. Remarkably 14 of the compounds at 100-μM concentration were found to reduce the enzymatic activity and 5 provided IC 50 values below 40 μM: manidipine (4.8 μM), boceprevir (5.4 μM), lercanidipine (16.2 μM), bedaquiline (18.7 μM), and efonidipine (38.5 μM). Structural analyses reveal a common cloverleaf pattern for the binding of the active compounds to the P1, P1’, and P2 pockets of M pro . Further study of the most active compounds in the context of COVID-19 therapy is warranted, while all of the active compounds may provide a foundation for lead optimization to deliver valuable chemotherapeutics to combat the pandemic.Keywords
All Related Versions
- Published version: ACS Medicinal Chemistry Letters, 11 (12), 2526.
This publication has 47 references indexed in Scilit:
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main proteaseCell Research, 2020
- Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug RepositionInternational Journal of Molecular Sciences, 2020
- Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofurNature Structural & Molecular Biology, 2020
- Anti-HCV, nucleotide inhibitors, repurposing against COVID-19Life Sciences, 2020
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitorsScience, 2020
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitorsNature, 2020
- Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoVChemBioChem, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003